DARE Dare Bioscience Inc.

0.77
-0.01  -2%
Previous Close 0.78
Open 0.76
Price To Book 3.33
Market Cap 12,769,483
Shares 16,683,411
Volume 53,923
Short Ratio
Av. Daily Volume 341,396

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 4Q 2020.
Sildenafil Cream, 3.6%
Female Sexual Arousal Disorder (FSAD)
Top-line data due 4Q 2019.
Ovaprene
Contraception
Phase 3 trial to be initiated 4Q 2019.
DARE-BV1
Bacterial Vaginosis
Phase 1 trial planned for 2019.
DARE-HRT1
Hormone replacement therapy

Latest News

  1. Edited Transcript of DARE earnings conference call or presentation 14-Aug-19 8:30pm GMT
  2. Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update
  3. Daré Bioscience Rallies On FDA Designation For Bacterial Vaginosis Drug
  4. Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis
  5. Daré Announces Presentation of Positive Clinical Findings for Vaginal Administration of Novel Formulation of Clindamycin Phosphate for the Treatment of Bacterial Vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology
  6. Daré Bioscience to Host Second Quarter 2019 Financial Results and Company Update Conference Call and Webcast
  7. Daré Announces Presentation of Two Posters at the 2019 Controlled Release Society Annual Meeting & Exposition
  8. Daré Bioscience Announces 2019 AAPS Best Abstract Award for Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model
  9. Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors
  10. The Daré Bioscience (NASDAQ:DARE) Share Price Is Down 35% So Some Shareholders Are Getting Worried
  11. Daré Bioscience Completes Recruitment in Pre-Pivotal Trial Of Monthly Woman-Controlled, Hormone-Free Contraceptive Candidate, Ovaprene®
  12. Daré Bioscience, Inc. Announces Positive Results in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
  13. Daré Bioscience to Present at the 2019 BIO International Convention
  14. DARE: Several Important Milestones, Including Ovaprene PCT Read-Out, Anticipated Later This Year
  15. Edited Transcript of DARE earnings conference call or presentation 14-May-19 8:30pm GMT
  16. Daré Bioscience Reports First Quarter 2019 Financial Results and Company Update
  17. Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research
  18. Daré Bioscience to Host First Quarter 2019 Financial Results and Company Update Conference Call and Webcast
  19. Edited Transcript of DARE earnings conference call or presentation 4-Apr-19 12:30pm GMT
  20. Dr. James Simon, Award-Winning Physician, Presents on Ovaprene® as a Promising Novel Non-Hormonal Contraceptive Method in Clinical Development